CDK4/6-related inhibitors from a medicinal chemistry perspective: Research advances in the past six years (2020-2025).
Cyclin-dependent kinase 4/6 (CDK4/6), as an important kinase regulating cell cycle progression, exhibits functional abnormalities closely associated with the initiation and progression of various cancers. Consequently, targeted inhibition of CDK4/6 represents a valuable and promising therapeutic strategy for cancer tre...